Non-Exec Board Member
Per Falk
CEO at GC Holding AG. Per joined GC as a board member in 2022 and was appointed CEO in October 2024.
Prior to joining GC Holding AG, Per was President and CSO in Ferring Pharmaceuticals. He has also held executive and senior leadership positions at Novo Nordisk and AstraZeneca in research, medical and clinical development roles.
For over 30 years, Per has been investigating and evolving microbiome science, from a scientific and application perspective, and has been holding faculty positions at some of the leading institutions to advance research in this field. He has held the role of Associate Professor at the Karolinska Institute, Sweden and the Washington University School of Medicine, USA.
Per is a qualified medical doctor and also has a Ph.D. in Biochemistry and Clinical Chemistry.